



October 2017

Dear Healthcare Provider,

The information contained here may be very important to your practice. Please take a moment to review this document.

PCL ALVERNO PARTNERS WITH CORDANT HEALTH SOLUTIONS™

Oral fluids drug testing has transitioned to Cordant Health Solutions and the changes occurring include the removal of acetaminophen, PCP and Propoxyphene on the drug screen panel, with the addition of Ethanol. Please check our collection manual on our website for more details <https://www.testmenu.com/alvernolabs>

NEW REFERENCE RANGE CA 15-3

Beckman Coulter has completed their evaluation of the upper reference limit (URL) for the CA 15-3 assay on their Dxl Analyzers. The previous URL was <31.3. The new URL will improve the sensitivity for patients in non-remission. The new reference range **CA 15-3: ≤ 23.5 U/mL** will be in effect October 2, 2017.

ROUTINE COAGULATION REPORTING CHANGES

PCL Alverno has recently moved to a system-wide standardization of normal reference ranges for routine coagulation testing using our new ACL TOP coagulation platform. The updated reference ranges can be found on page two.

SEE PAGE THREE FOR AN UPCOMING IMPROVEMENT TO POSITIVE BLOOD CULTURE ORGANISM IDENTIFICATION.

SEE PAGE FOUR TO SEE CHANGES COMING IN TEST RESULT FORMATTING FOR FAXED AND MAILED REPORTS.

Find Us on Facebook, LinkedIn and Google Plus!

2434 Interstate Plaza Drive, Hammond, IN 46324
toll free 800.937.5521 · phone 219.989.3700 · fax 219.989.3900

www.PCLAlverno.com



ROUTINE COAGULATION REPORTING CHANGES

PCL Alverno has recently moved to a system-wide standardization of normal reference ranges for routine coagulation testing using our new ACL TOP coagulation platform. The updated reference ranges are listed below. Please be reminded that the D-dimer cut off for screening patients for DVT/PE will still remain 500 ng/mL FEU, and that the normal reference range should be referred to when evaluating patients other than screening for DVT/PE.

Test Name	New Reference Range
PT	10.1 – 13.1 sec
aPTT	25 – 36 sec
aPTT (Heparin Therapy)	64.6 – 89.9 sec (65 – 90 sec)
Fibrinogen	163 – 463 mg/dL
DDimer	0 – 622 ng/mL FEU**

**The D-dimer cut off for DVT/PE will remain at 500 ng/mL FEU. The normal reference range is used for applications other than screening for DVT/PE.



MOLECULAR TESTING FOR POSITIVE BLOOD CULTURES Continuous Improvement for Rapid Resulting

Fourth Quarter 2017

PCL Alverno is pleased to announce the addition of Molecular Testing to augment our positive blood culture algorithm. In September 2014, PCL Alverno began using MALDI-TOF mass spectrometry technology for rapid identification of organisms from positive blood culture media.

Soon, Molecular PCR testing will be added to detect MRSA in specimens identified as *Staphylococcus aureus* by MALDI-TOF. In addition, PCR will be used for rapid detection of VRE *Enterococcus* species and CRE *Klebsiella pneumoniae*.

PCL Alverno will also use PCR technology to assist with positive blood culture organism identification when the MALDI-TOF is unable to provide a reportable result. This addition of rapid resistance marker detection is another step to providing the best patient care available through reduced TAT of critical results.



NEW FORMAT FOR FAXED/MAILED RESULTS

Please note that if you receive your results by fax or via USPS mail, you will see a new result format. All other types of results will remain the same (EMR, Epic, Atlas, CareEvolve, IHIE, etc.) The results are easier to read and the update has been made from requests by our clients.



2434 Interstate Plaza Drive
Hammond, IN 46324
1 - 800 - 937 - 5521
Elisabeth C. Shearon, M.D., Medical Director

Patient: DOE, JOHN
DOB: 02/15/1968 Age: 49 Sex: M
MRN: N20000000014
Billing #: N20000000019
Order #: S52800001

Location: TEST CLIENT FOR INTERFACES
Room: Bed:
Requested by: TEST, DOCTOR
Copy to: TEST, DOCTOR

MICROBIOLOGY

Source: Clean Catch Urine Collected: 09/28/17 09:39
Site: Received: 09/28/17 09:39

Urine Culture *** FINAL * 09/28/17 15:17

09/28/17 Identifications performed by MALDI TOF Mass Spectrometry were developed and performance characteristics were determined by PCL Alverno, Hammond, IN.

Isolate #01 *Proteus mirabilis*
>100,000 cfu/ml
Identified by MALDI TOF Mass Spectrometry.

Isolate	ORG# 01
ANTIBIOTICS	Mc SUR
Ampicillin	>16 R
Amp/Sulbactam(c)	>16/8 R
Cefazolin	<=8 S
Cefepime	<=8 S
Cefotetan	<=16 S
Cefuroxime	<=4 S
Cephalexin	<=8 S
Amox/K Clavate(c)	16/8 I
Ciprofloxacin	2 I
Trimethoprim/Sulfame	<=2/38 S
Ertapenem	<=2 S
Gentamicin	<=4 S
Levofloxacin	<=2 S
Meropenem	<=4 S
Piperacillin/Tazobactam	<=16 S
Tobramycin	<=4 S

S= Susceptible I= Intermediate R= Resistant

PCL Alverno
2434 Interstate Plaza Drive
Hammond, IN 46324
Elisabeth C. Shearon, M.D., Medical Director

Patient: DOE, JOHN
DOB: 02/15/1968 Age: 49 Sex: M
MRN: N20000000014
Billing #: N20000000019

Location: TEST CLIENT FOR INTERFACES
Room: Bed:
Admit Date: 09/28/17
Attending Physician: TEST, DOCTOR

Order #: S52800005
D/T Ordered: 09/28/17 15:18
Requested by: TEST, DOCTOR
Copy to:

BLOOD BANK

Blood Type: A POS
Previous Transfusion:

Test results:

Blood Type A POS 09/28/17 15:23



2434 Interstate Plaza Drive
Hammond, IN 46324
1 - 800 - 937 - 5521
Elisabeth C. Shearon, M.D., Medical Director

Patient: DOE, JOHN
DOB: 02/15/1968 Age: 49 Sex: M
MRN: N20000000014
Billing #: N20000000019
Order #: S52800002

Location: TEST CLIENT FOR INTERFACES
Room: Bed:
Requested by: TEST, DOCTOR
Copy to: TEST, DOCTOR

CHEMISTRY

Test Name	Result	ABN	Ref-Ranges	Units	Site
COLLECTED 09/28/17 09:44					

Electrolytes

Sodium	142		133-144	mEq/L	
Potassium	5.1		3.5-5.1	mEq/L	
Chloride	97	L	98-107	mEq/L	
Carbon Dioxide	23.0		21.0-31.0	mEq/L	
Anion Gap	22.0	H	3.6-11.0		

HEMATOLOGY

Test Name	Result	ABN	Ref-Ranges	Units	Site
COLLECTED 09/28/17 09:44					

Complete Blood Count

WBC	6.5		4.0-11.0	x1000/uL	
RBC	4.52		4.34-5.60	xMil/uL	
HGB	13.6		13.0-17.0	g/dL	
HCT	44.3		38.6-49.2	%	
MCV	87.5		80.0-100.0	fL	
MCH	27.6		26.0-34.0	pg	
MCHC	34.2		32.5-35.8	g/dL	
RDW	12.1		11.9-15.9	%	
PLT	350		150-450	x1000/uL	

COAGULATION

Test Name	Result	ABN	Ref-Ranges	Units	Site
COLLECTED 09/28/17 09:44					

Protome

Protome/No Therapy	11.2		10.2-12.9	SEC	
INR	1.2				